SciELO - Scientific Electronic Library Online

vol.145 issue4Sedentary lifestyle is associated with metabolic and cardiovascular risk factors independent of physical activityEffects of a mindfulness intervention in Chilean high schoolers author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Revista médica de Chile

Print version ISSN 0034-9887


SOTO V, Álvaro et al. Intravenous thrombolysis for acute ischemic stroke. A four years’ experience in a Chilean public hospital. Rev. méd. Chile [online]. 2017, vol.145, n.4, pp.468-475. ISSN 0034-9887.

Background: Intravenous thrombolysis (IVT) with alteplase (tissue plasminogen activator) is the standard pharmacological treatment in acute ischemic stroke (AIS), reducing disability in patients. Aim: To report the results a thrombolysis protocol during four years in a regional public hospital. Material and Methods: Data from 106 consecutive patients aged 68 ± 13 years (57% men) who were treated with IVT, from May 2012 until April 2016, was analyzed. Results: The median door-to-needle time was 80 minutes (interquartile range = 57-113). The median National Institute of Health Stroke Scale (NIHSS) scores on admission and at discharge were was 11.5 and 5 points respectively. At discharge, 27% of hospitalized patients had a favorable outcome (n = 99), defined as having 0 to 1 points in the modified Rankin scale. Symptomatic intracerebral hemorrhage and mortality rates were 5.7 and 13.1%, respectively. The thrombolysis rate rose from 0.7% in 2012 to 6% in 2016. Conclusions: The implementation of 24/7 neurology shifts in the Emergency Department allowed us to increase the amount and quality of IVT in our hospital, as measured by the rate of thrombolysis and by process indicators such as door-to-needle time.

Keywords : Fibrinolytic Therapy; Stroke; Time-to-Treatment; Thrombolytic Therapy; Tissue Plasminogen Activator.

        · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License